This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Antitrust - Corcept Therapeutics - Optime Care - Teva's litigation over alleged monopolization of Korlym (US)

Teva Pharmaceuticals filed a US antitrust complaint accusing Corcept Therapeutics and Optime Care of illegally blocking generic competition for Corcept’s branded drug Korlym, a treatment for Cushing’s disease. According to the complaint, Corcept manipulated the patent system to delay Food and Drug Administration approval of Teva’s generic competitor by years, and abused the courts through sham litigations that served no purpose but to forestall competition. Teva also claimed Corcept and Optime entered into an unprecedented exclusive-dealing agreement that requires Optime to distribute Corcept’s brand Korlym product but expressly forbids it from distributing any competing products, including Teva’s generic.

To add details to this portfolio regarding legal or economic representatives, please contact editors@mlex.com

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.


  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login